Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidino
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... of the "Telemedicine and Mobile Healthcare Solutions, ... - 2020" report to their offering. ... are all terms that pertain to the use ... provide remote clinical/non-clinical healthcare services. They form the ...
(Date:3/3/2015)... 2015  Cyberonics, Inc. (NASDAQ: CYBX ), ... and management of epilepsy, today announced it will participate ... 11, 2015, in Miami . ... Executive Officer, will speak at 1:05 PM Eastern Time.  ... format, and no formal materials will be presented.  A ...
(Date:3/3/2015)... Today, the Partnership for Prescription Assistance ... research companies, unveiled a redesigned website ... and caregivers with faster, easier access to information ... assistance programs. Since its launch ... engage, educate and empower patients and caregivers to ...
Breaking Medicine Technology:Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 2Global Telemedicine and Mobile Healthcare Solutions, Services, and Devices: Market Analysis and Forecasts 2015 - 2020 3Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 2
... TAXUS(R) Element(TM) Stent now available in select markets ... (NYSE: BSX ) today announced the ... Coronary Stent System in select markets worldwide. ... chromium alloy engineered specifically for coronary stent applications ...
... Pa., May 18 MEDRAD Interventional(TM)/Possis(R) today announced ... the Paccocath(R) Technology closer to market as an ... the United States and Europe who suffer from ... selection of physician investigators for U.S. clinical trials ...
Cached Medicine Technology:Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 2Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 3Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 4Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data 5
(Date:3/4/2015)... TheraBreath is proud to announce a new ... also help with overall health. , Many health experts ... ward off bad bacteria that can cause unwanted infections. While ... own, most will need the help of a probiotic to ... levels. , Packed with the S. salivarius M18 & K12 ...
(Date:3/4/2015)... 2015 Theme and plugin developers from ... for Final Cut Pro X entitled ProFont NoteBook , “ProFont ... any FCPX editors project.” Said Christiana Austin, CEO of Pixel ... add animated font to their FCPX media.” , With ProFont ... within Final Cut Pro X. ProFont Notebook offers users up ...
(Date:3/4/2015)... City View producers are pleased ... vicinity. The city of 90 neighborhoods, each with its own ... for everyone. With many outdoor parks, music and fine ... a metropolitan area everyone should visit once in their lifetime. ... bridges. The stunning cable program will be broadcast on PCNC ...
(Date:3/3/2015)... MA (PRWEB) March 04, 2015 ... educational facilities design and construction event for New ... Boston Massachusetts announced key building envelope related workshops. ... , Workshops include: , Curtain Walls ... in many health care and laboratory facilities are ...
(Date:3/3/2015)... New York (PRWEB) March 03, 2015 ... tactics used to market the atypical antipsychotic medication ... U.S. According to court documents, the South Carolina ... finding that Johnson & Johnson’s Janssen Pharmaceuticals unit ... serious risks. However, while the Court’s February 25th ...
Breaking Medicine News(10 mins):Health News:TheraBreath introduces a new line of probiotic lozenges that strengthen the body’s ability to fight germs 2Health News:Announcing a New Title Pack from Pixel Film Studios, ProFont NoteBook for Final Cut Pro X 2Health News:City View Television Show Will Air in Pittsburgh, PA 2Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 2Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 3Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 4Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 5Health News:Building Envelope Code and Regulation Sessions at MED-Ed Facilities 6Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Ruling Upholding South Carolina Jury Decision in Risperdal Marketing Case 3
... new ... nationwide survey shows, JACKSONVILLE, Fla., Oct. 29 ... on November 4 and see fewer hours of,daylight, findings from a ... may not be seeing while,driving in the dark. Of further concern, ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of pharmaceutical ... the company,s Chairman and Chief Executive,Officer received the ... China,2007 Award. This prestigious award was presented to ... 26 in the China World Hotel, Beijing, China. ...
... blood pressure and are at greater risk of hypertension ... quality and exhibit a smaller nighttime decrease in blood ... , This ethnic difference in blood pressure dipping may ... of hypertension, says Dr. Joel Hughes, Kent State assistant ...
... Digital Pen Technology Allows Hospitals, Medical ... PHILADELPHIA, Oct. 29 Today at the ... the,Docuscan Patient Registration system, an innovative solution for ... the chance of data entry errors. With ...
... America how they ,Think About Their Drink, ST. LOUIS, Oct. 29 , ... the Think About Your Drink ... entered the photo contest by submitting a ... part of a nationwide education campaign, ...
... Another disease can be added to the list ... that smoking increases the risk of developing psoriasis, ... risk decreases only slowly after quitting. Investigators from ... the Harvard School of Public Health, all in ...
Cached Medicine News:Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 2Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 3Health News:Blinded by the Light? Vision Problems and Visual Discomfort Make Driving in the Dark Difficult, Uncomfortable for Most Americans 4Health News:WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award 2Health News:WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award 3Health News:Pearson Introduces 'Smart' Technology for Collecting Patient Registration Information 2Health News:Pearson Introduces 'Smart' Technology for Collecting Patient Registration Information 3Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 3Health News:New study shows smoking increases risk of psoriasis 2
... recommended for evaluating vitreoretinal relationships ... in the management of dislocated ... lens for small pupil fundus ... It provides a slightly wider ...
... new MagPlus Iridectomy Lens enhances iridectomy ... viewing area (than conventional iridectomy lens ... The bulb on this lens has ... lens) to 11.7mm. The MagPlus comes ...
... advanced fundus laser lens design with Volk ... magnification viewing and treatment of the optic ... aspheric optics provide improved performance over existing ... comes standard with LaserWindow® for optimal laser ...
... with 10mm diameter contact surface is ideal ... prematurety (ROP) and other infant conditions. It ... in the diagnosis and treatment of the ... with narrow palpebral fissures. Developed with Hideyuki ...
Medicine Products: